Northwest Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-60.2M | $-83.8M | $-62.6M | $-105.0M | $179.1M | $-529.8M | $-20.8M | $-35.8M |
| Depreciation & Amortization | $2.1M | $1.7M | $1.5M | $1.3M | $324.0K | $87.0K | $21.0K | $1.3M |
| Depreciation | $1.9M | $1.7M | $1.5M | $1.3M | $300.0K | $87.0K | $21.0K | $1.3M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | $3.6M | — | — | — | — | — |
| Net Cash from Operating Activities | $-44.8M | $-57.0M | $-53.6M | $-52.8M | $-38.3M | $-32.1M | $-31.9M | $-34.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.5M | $1.0M | — | — | — | — | $171.0K | — |
| Business Acquisitions | — | — | — | — | — | $1.5M | — | — |
| Net Cash from Investing Activities | $-1.8M | $-1.0M | $-3.4M | $-2.9M | $-6.0M | $-8.1M | $-360.0K | $45.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $49.3M | $56.8M | $52.8M | $42.0M | $48.1M | $52.7M | $10.0M | $7.9M |
| Net Change in Cash | $865.0K | $49.0K | $-4.8M | $-8.2M | $5.2M | $9.6M | $-21.9M | $22.1M |
| Free Cash Flow | $-46.3M | $-58.0M | — | — | — | — | $-32.0M | — |